GRADE 2 FOLLICULAR LYMPHOMA

This early-phase study tests whether adding the drug acalabrutinib to a type of immune cell therapy (CAR T-cells) can safely treat B-cell lymphoma, a cancer of the immune system. About 23 adults with certain aggressive or slow-growing lymphomas will receive the combination. The g…

This study is for people with a slow-growing type of blood cancer called follicular lymphoma that has come back or stopped responding to treatment. Researchers are testing whether adding other drugs to a standard immunotherapy (obinutuzumab) can improve results. About 73 adults w…

This study tests a combination of three drugs (obinutuzumab, ibrutinib, and venetoclax) in 40 people with untreated follicular lymphoma, a slow-growing blood cancer. The goal is to see if the combination works better than each drug alone at shrinking tumors and controlling the di…

This early-phase study tests a combination of three drugs (obinutuzumab, venetoclax, and lenalidomide) in 22 adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goal is to find the safest dose and see if the combination can shri…

This study tests a combination of two drugs, obinutuzumab and ibrutinib, as the first treatment for people with slow-growing non-Hodgkin's lymphoma. The goal is to see how well the drugs shrink or eliminate cancer. About 30 adults with newly diagnosed lymphoma will receive this t…